Eli Lilly boss calls out Australia on Mounjaro and Trump over kids vaccines

Eli Lilly Pharmaceuticals CEO David Ricks criticized the Australian government over its stance on pricing for the diabetes and weight loss drug Mounjaro, stating that the country’s valuation of the medication was too low. The comments came during an interview with 7.30, a program broadcast on Australia’s ABC television network. Ricks expressed frustration over the ongoing negotiations to list Mounjaro on the Pharmaceutical Benefits Scheme (PBS), which provides subsidized medications to Australians. Despite a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC), Eli Lilly had previously rejected the proposal, citing that the price conditions set by the Australian government were “unrealistic and unviable.” The company argued that the proposed price was significantly lower than any other reimbursed price globally, potentially undermining its ability to invest in research and development. Ricks acknowledged the challenges of reaching an agreement but emphasized that the company remained committed to finding a solution that would allow more Australians with Type 2 diabetes to access the drug. He noted that while price was a key concern, the company was open to exploring adaptive schemes and alternative approaches to ensure affordability without compromising the value of the medicine. “We definitely want Mounjaro to be listed on the PBS scheme,” he stated. However, Ricks warned that setting prices too low in Australia could have ripple effects worldwide, potentially devaluing the drug globally and impacting future innovation. In addition to the Mounjaro controversy, Ricks addressed concerns regarding recent changes to the U.S. childhood vaccination schedule under the Trump administration. The White House issued an executive order reducing the number of diseases included in the recommended immunization plan for children, removing six vaccines from the current schedule. These include RSV, Hepatitis A, Hepatitis B, Meningococcal ACWY, Rotavirus, and Influenza. This move has sparked debate, particularly given that Robert F. Kennedy Jr., who serves as the U.S. Secretary of Health and Human Services, is known for his skepticism toward vaccines. Ricks expressed hope that the U.S. scientific community would scrutinize the changes, especially the claim that vaccinations increase autism rates, a theory that lacks scientific support. While Ricks admitted he had not reviewed the full details of the executive order, he stressed the importance of basing decisions on solid evidence. “Patients and parents want to know what does cause autism, that’s a natural thing, but we need evidence before we take changes to the schedule,” he said. He reiterated that there is no credible link between vaccines and autism, and that individuals on the autism spectrum often lead fulfilling lives. Ricks urged caution in altering public health policies without thorough evaluation. The situation highlights broader tensions between pharmaceutical companies and governments over drug pricing, as well as growing political debates surrounding public health initiatives. In Australia, the ongoing negotiations over Mounjaro reflect the complex interplay between corporate interests and healthcare accessibility. Meanwhile, in the United States, the revised vaccination guidelines underscore the influence of political figures on medical policy, raising questions about the role of science in shaping public health decisions. As these issues continue to unfold, both countries will likely face further scrutiny from industry leaders, scientists, and the general public.